article Open AccessTop 1% cited

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Psychopharmacology · 2017 · Vol. 235(2) · pp. 399–408

Robin Carhart‐Harris✉(Imperial College London)Mark Bolstridge(South London and Maudsley NHS Foundation Trust)Camilla Day(Imperial College London)James Rucker(Imperial College London)R. Watts(Imperial College London)David Erritzøe(Imperial College London)Mendel Kaelen(Imperial College London)Bruna Giribaldi(Imperial College London)Michael Bloomfield(University College London)Stephen Pilling(University College London)James A. Rickard(Barts Health NHS Trust)Benjamin Forbes(King's College London)Amanda Feilding(Beckley Foundation)David Taylor(South London and Maudsley NHS Foundation Trust)Valerie H. Curran(University College London)D.J. Nutt(Imperial College London)

View via DOI Full-text PDF

Abstract

Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.

Psychedelics and Drug Studies Chemical synthesis and alkaloids Diverse academic research themesPsilocybinDepression (economics)PsychologyPsychiatryHallucinogenTreatment-resistant depressionClinical psychologyPsychotherapistMedicineAnxiety

MeSH terms

Psychosocial Support SystemsAdultAntidepressive AgentsCombined Modality TherapyDouble-Blind MethodFeasibility StudiesFemaleFollow-Up StudiesHallucinogensHumansMaleMiddle AgedPsilocybinTime FactorsTreatment Outcome